Roche and Immatics Collaborate to Evaluate IMA101 + Tecentriq (atezolizumab) for Solid Cancers
Shots:
- The companies enter into a clinical research collaboration for the evaluation of efficacy and safety of immunotherapy combining Roche’s Tecentriq (atezolizumab) with Immatics’ IMA101 in solid tumors
- In H2’19- companies plan for the onset of the trial based on ACTolog IMA101-101 study protocol at MD Anderson Cancer Center to kill cancer cells by blocking inhibitory immune checkpoints
- Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptor. IMA101 is a P-I candidate based on Immatics’s ACTolog therapy (endogenous T-cell therapy) targeted for multiple advanced/ metastatic solid tumors
Ref: Immatics | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com